NCT07239440Not yet recruitingPhase 2
Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
A Multicenter, Double-blind, Active-controlled, Randomized, Parallel Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
Source: ClinicalTrials.gov · Last updated 20 Nov 2025
Brief summary (registry, in English)
This study is a multicenter, double-blind, active-controlled, randomized, parallel clinical trial to evaluate the efficacy and safety of DA-2811 when added to ongoing BT-1 and BT-2 combination therapy in patients with type 2 diabetes who have inadequate glycemic control
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 288 (estimated)
- First submitted
- 16 Nov 2025
- Start date
- Nov 2025
- Primary completion date
- Dec 2026
- Lead sponsor
- Dong-A ST Co., Ltd.
- Diseases
- Type 2 diabetes
- NCT number
- NCT07239440
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 288
- From Nov 2025 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with type 1 diabetes, secondary diabetes, gestational diabetes, diabetic coma or -pre-coma, metabolic acidosis including lactic acidosis and diabetic ketoacidosis
- Patients with a medical history of New York Heart Association(NYHA) class III\~IV heart failure or with congestive heart failure, acute and unstable heart failure
- Patients with severe infectious disease or severe traumatic systemic disorders
- Patients with hypopituitarism or adrenal insufficiency, pulmonary infarction, severe pulmonary dysfunction and other hypoxemia
Other
- Patients with galactose intolerance, lapp lactase deficiency, glucosegalactose malabsorption
Who the study is looking for
- Patients with type II diabetes mellitus aged 19 years or older
- Patients with fasting plasma glucose≤270mg/dL at the screening visit
- Patients with 18.5kg/m\^2≤BMI≤40kg/m\^2 at the screening visit
- Patients who have signed an informed consent themselves after receiving detailed explanation about the clinical study
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Samsung Medical Center Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.